MASSY, France--(

法国马西-(

BUSINESS WIRE

商业热线

)--

)--

MITEM PHARMA, a French-based pharmaceutical company dedicated to Drugs of Major Therapeutic Interest (DMTI), is pleased to announce that it has acquired the rights to FLISINT

MITEM PHARMA是一家总部位于法国的制药公司，专注于主要治疗药物（DMTI），它很高兴地宣布，它已经获得了FLISINT的权利

®

®

, an infectious disease DMTI, from SANOFI WINTHROP INDUSTRIE (Gentilly - France).

，一种传染病DMTI，来自赛诺菲温思罗普工业公司（法国Gentilly）。

FLISINT

FLISINT

®

®

(fumagillin) is recognised as the only treatment capable of overcoming

（烟曲霉素）被认为是唯一能够克服的治疗方法

Enterocytozoon bieneusi

Enterocytozoon 良性

microsporidia infections. This opportunistic germ develops in clinical situations of immunosuppression (e.g. AIDS or immunosuppression for organ transplantation). There is no equivalent therapeutic alternative in the world.

微孢子虫感染。这种机会性细菌在免疫抑制的临床情况下发展（例如艾滋病或器官移植的免疫抑制）。世界上没有同等的治疗替代品。

Since FLISINT

FLISINT

®

®

ceased to be marketed in 2019, the FRIPHARM® (Fabrication Recherche Innovation Pharmaceutique; Hospices Civils de Lyon) university hospital platform has been manufacturing the product as a magistral preparation, helping patients with the last remaining stock of active ingredient available from SANOFI.

FRIPHARM®（Fabrication Recherche Innovation Pharmaceutique；Respices Civils de Lyon）大学医院平台于2019年停止销售，一直在生产该产品作为地方制剂，帮助患者获得赛诺菲最后剩余的活性成分。

MITEM PHARMA has set itself the task of making available to patients and medical staff essential medicines that have been taken off the market.

MITEM PHARMA为自己设定了一项任务，即向患者和医务人员提供已从市场上撤出的基本药物。

At the request of the FRIPHARM® platform team, MITEM PHARMA is working to update and relaunch the active ingredient production and FLISINT

应FRIPHARM®平台团队的要求，MITEM PHARMA正在努力更新和重新启动活性成分生产和FLISINT

®

®

manufacturing processes.

制造过程。

FLISINT

FLISINT

®

®

currently has marketing authorization in France but is the subject of numerous requests for exceptional supplies abroad (Europe; USA; Argentina; Australia; etc.).

目前在法国拥有上市许可，但在国外（欧洲、美国、阿根廷、澳大利亚等）有许多特殊用品的需求。

This acquisition underpins MITEM PHARMA's growth strategy in the DMTI sector and its determination to serve all territories affected by diseases which, while rare, are often fatal.

此次收购巩固了MITEM PHARMA在DMTI行业的增长战略，以及为所有受疾病影响的地区提供服务的决心，这些疾病虽然罕见，但往往是致命的。

MITEM PHARMA, backed by the TECHLIFE CAPITAL investment fund specialising in healthcare, is bringing its expertise in DMTIs and its marketing network in over 60 countries to bear on these products.

由专门从事医疗保健的TECHLIFE资本投资基金支持的MITEM PHARMA正在将其在DMTI方面的专业知识及其在60多个国家的营销网络应用于这些产品。

Claude-Alain CUDENNEC and Éric THIERRY, founders of MITEM PHARMA

, said: 'The acquisition of FLISINT

，表示：“收购FLISINT

®

®

(fumagillin) confirms MITEM PHARMA's determination to provide patients and medical teams with concrete solutions in the fight against serious diseases. MITEM PHARMA is taking over from the remarkable efforts made by FRIPHARM’s® platform to avoid a disruption in the pharmaceutical availability of fumagillin..

。MITEM PHARMA正在接管FRIPHARM®平台所做的卓越努力，以避免烟曲霉素的药物供应中断。。

About MITEM PHARMA

关于MITEM PHARMA

MITEM PHARMA is a French pharmaceutical laboratory specialising in

MITEM PHARMA是一家法国制药实验室，专门从事

Drugs of Major Therapeutic Interest (DMTI). MITEM PHARMA's mission is to improve patients' quality of life by ensuring the availability of important medicines, which are the only treatments for severe diseases, but whose supply shortages cause public health risks. Working with partner doctors and patient associations, the company identifies these situations, and buys back, upgrades, improves or develops these major medicines to guarantee access to appropriate care.

主要治疗药物（DMTI）。MITEM PHARMA的使命是通过确保重要药物的可用性来改善患者的生活质量，这些药物是治疗严重疾病的唯一方法，但其供应短缺会导致公共卫生风险。该公司与合作医生和患者协会合作，确定这些情况，并回购、升级、改进或开发这些主要药物，以确保获得适当的护理。

MITEM PHARMA is constantly adapting to patients, the environment and market developments to make DMTIs accessible at every stage of life, particularly in the fields of haematology, endocrinology, emergency cardiology, medical dermatology and now infectious diseases. MITEM PHARMA currently has an international presence in over 60 countries..

MITEM PHARMA不断适应患者、环境和市场发展，使DMTI在生命的每个阶段都可以使用，特别是在血液学、内分泌学、急诊心脏病学、医学皮肤病学以及现在的传染病领域。MITEM PHARMA目前在60多个国家拥有国际业务。。

For more information:

有关更多信息：

www.mitempharma.com

www.mitempharma.com